DENVER--(

丹佛--(

BUSINESS WIRE

商业热线

)--

)--

TriSalus Life Sciences

TriSalus生命科学

®

®

, Inc.

，公司。

(“TriSalus” or the “Company”) (Nasdaq: TLSI), TriSalus Life Sciences seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today the publication of research titled, .

（“TriSalus”或“公司”）（纳斯达克：TLSI），TriSalus Life Sciences寻求通过将我们的创新递送技术与标准护理疗法和我们的研究性免疫疗法相结合来改变实体瘤患者的预后，今天宣布了名为。

“Pressure Enabled Drug Delivery (PEDD) Significantly Increases Intraarterial Delivery of Embolic Microspheres to Liver Tumors in a Porcine Model,”

“在猪模型中，压力使能药物递送（PEDD）显着增加栓塞微球向肝肿瘤的动脉内递送，”

in the peer-reviewed Journal of Vascular and Interventional Radiology. The study, conducted in a transgenic tumor model, highlights the superior performance of the TriNav Infusion System in delivering Embospheres® into liver tumors when compared to delivery with a traditional microcatheter.

在同行评审的《血管与介入放射学杂志》上。这项在转基因肿瘤模型中进行的研究强调了与传统微导管相比，TriNav输注系统在将Embospheres®输送到肝肿瘤中的优越性能。

Key Findings:

主要发现：

Improved Tumor Penetration:

改善肿瘤穿透性：

PEDD achieved a 227 % increase (p=0.029) in the concentration of fluorescently labeled Embospheres within tumor tissue compared to a traditional microcatheter.

与传统的微导管相比，PEDD在肿瘤组织内荧光标记的栓子浓度增加了227%（p=0.029）。

Improved Tumor Selectivity:

提高肿瘤选择性：

The tumor-to-normal (T:N) ratio rose from 2.7 for a traditional microcatheter to 4.2 when delivered by PEDD, indicating more precise tumor targeting and reduced off-target delivery.

当通过PEDD递送时，肿瘤与正常（T:N）的比率从传统微导管的2.7上升到4.2，表明更精确的肿瘤靶向和减少的脱靶递送。

Increased Peritumoral Delivery:

肿瘤周围分娩增加：

Delivery to peritumoral regions increased by 209% (p=0.045), demonstrating PEDD's ability to overcome challenging tumor associated microenvironments.

向肿瘤周围区域的递送增加了209%（p=0.045），证明了PEDD克服具有挑战性的肿瘤相关微环境的能力。

“This study further validates the potential of TriNav using the PEDD approach to transform the treatment of liver tumors,” said Bryan F. Cox, Ph.D., Chief of Research for TriSalus. “By significantly enhancing therapeutic delivery and sparing healthy tissue, PEDD offers a promising advancement for patients whose outcomes may be limited by conventional delivery methods.”.

TriSalus研究负责人Bryan F.Cox博士说：“这项研究进一步验证了TriNav使用PEDD方法改变肝肿瘤治疗的潜力。”。“通过显着增强治疗性递送和保留健康组织，PEDD为结果可能受到常规递送方法限制的患者提供了有希望的进展。”。

The study was conducted using a transgenic porcine (Oncopig) liver tumor model, employing fluorescent imaging and advanced deep-learning algorithms to quantify therapeutic delivery with millimeter-scale resolution. Results showed the TriNav Infusion System using the PEDD approach markedly outperforms traditional microcatheters in delivering embolic microspheres into liver tumors..

该研究使用转基因猪（Oncopig）肝肿瘤模型进行，采用荧光成像和先进的深度学习算法以毫米级分辨率量化治疗递送。结果显示，使用PEDD方法的TriNav输注系统在将栓塞微球输送到肝肿瘤中方面明显优于传统的微导管。。

These findings add to the growing body of clinical and real-world evidence supporting PEDD's ability to improve the delivery of therapeutic agents for patients with primary and metastatic liver cancers.

这些发现增加了越来越多的临床和现实证据，支持PEDD改善原发性和转移性肝癌患者治疗药物输送的能力。

To read the full study, visit

要阅读完整的研究，请访问

here

在这里

.

.

About TriSalus Life Sciences

关于TriSalus Life Sciences

TriSalus Life Sciences® is an oncology focused medical technology business providing disruptive drug delivery technology with the goal of improving therapeutic delivery to solid tumors. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy.

TriSalus Life Sciences®是一家专注于肿瘤学的医疗技术业务，提供破坏性药物输送技术，旨在改善实体瘤的治疗效果。该公司的平台包括利用专有药物输送技术和临床阶段研究性免疫疗法的设备。

The Company’s two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD™) approach to deliver a range of therapeutics: the TriNav® Infusion System for hepatic arterial infusion of liver tumors as well as other solid tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors.

该公司的两个FDA批准的设备使用其专有的压力启用药物输送™（PEDD™）方法来提供一系列治疗方法：用于肝肿瘤以及其他实体瘤肝动脉输注的TriNav®输注系统和胰腺逆行静脉输注系统胰腺肿瘤。

PEDD is a novel delivery approach designed to address the anatomic limitations of infusion into solid tumors. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to limit delivery to normal tissue, creating the potential to improve patient outcomes.

PEDD是一种新型的递送方法，旨在解决输注到实体瘤中的解剖学限制。PEDD方法调节压力和流量的方式可以为肿瘤提供更多的治疗效果，并旨在限制向正常组织的输送，从而有可能改善患者的预后。

Nelitolimod, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials support the hypothesis that nelitolimod delivered via PEDD may have favorable immune effects within the liver and systemically.

Nelitolimod是该公司的研究性免疫治疗候选药物，旨在通过治疗许多肿瘤产生的免疫抑制环境来改善患者的预后，这可能使目前的免疫疗法对肝脏和胰腺无效。在压力激活的区域免疫肿瘤学™（PERIO）临床试验期间产生的患者数据支持以下假设：通过PEDD递送的奈利莫德可能在肝脏和全身内具有良好的免疫作用。

The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by PEDD are commonly present as well. Nelitolimod delivered by PEDD will be studied across several indications in an effort to address immune dysfunction and overcome drug delivery barriers in the liver and pancreas..

奈利托莫德的靶标TLR9在各种癌症类型中表达，并且通常也存在PEDD解决的机械障碍。PEDD提供的奈利托莫德将在多个适应症中进行研究，以解决免疫功能障碍并克服肝脏和胰腺中的药物输送障碍。。

In partnership with leading cancer centers across the country – and by leveraging deep immuno-oncology expertise and inventive technology development – TriSalus is committed to advancing innovation that improves outcomes for patients. Learn more at

TriSalus与全国领先的癌症中心合作，利用深入的免疫肿瘤学专业知识和创新技术开发，致力于推进创新，改善患者的预后。了解更多信息，请访问

trisaluslifesci.com

trisaluslivesci.com

and follow us on

继续关注我们

X (formerly Twitter)

X（前推特）

and

和

LinkedIn

LinkedIn

.

.

Forward-Looking Statements

前瞻性声明

Certain statements made in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.

本新闻稿中的某些声明是《证券法》第27A节和经修订的《1934年证券交易法》第21E节所指的“前瞻性声明”，并受1995年《私人证券诉讼改革法》所设安全港的约束。

Forward-looking statements may be identified by the use of words such as “become,” “may,” “intend,” “will,” “expect,” “anticipate,” “believe” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding TriSalus’s business, the commercial potential of its TriNav Infusion System, TriSalus’s proprietary PEDD approach, the potential therapeutic benefits and commercial potential of Nelitolimod, and TriSalus’s technologies and other products in development.

前瞻性陈述可以通过使用诸如“成为”、“可能”、“打算”、“将要”、“期望”、“预期”、“相信”或其他类似表达来识别，这些表达可以预测或指示未来的事件或趋势，或者不是历史事件的陈述。这些前瞻性声明包括但不限于关于TriSalus业务的声明，TriNav输液系统的商业潜力，TriSalus专有的PEDD方法，Nelitolimod的潜在治疗益处和商业潜力，以及TriSalus正在开发的技术和其他产品。

Such statements are subject to certain risks and uncertainties, including, but not limited to, those inherent in the process of developing and commercializing medical devices that are safe and effective for human use, discovering, developing and commercializing medicines that are safe and effective to use as human therapeutics, and the endeavor of building a business around such medical devices and medicines..

此类声明具有一定的风险和不确定性，包括但不限于开发和商业化人类使用安全有效的医疗器械过程中固有的风险和不确定性，发现、开发和商业化人类治疗安全有效的药物过程中固有的风险和不确定性，以及围绕此类医疗器械和药物建立业务的努力。。

TriSalus’s forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although TriSalus’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by TriSalus.

TriSalus的前瞻性陈述还涉及假设，如果这些假设从未实现或证明是正确的，则可能导致其结果与此类前瞻性陈述所表达或暗示的结果存在重大差异。尽管TriSalus的前瞻性陈述反映了其管理层的诚信判断，但这些陈述仅基于TriSalus目前已知的事实和因素。

As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning TriSalus’s products and programs are described in additional detail in TriSalus’s annual report on Form 10-K, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission (the 'SEC') and available at the SEC's website (.

因此，请注意不要依赖这些前瞻性声明。与TriSalus产品和计划有关的这些风险和其他风险在TriSalus的年度报告中以表格10-K和最新的表格10-Q进行了详细描述，这些表格已向美国证券交易委员会（“SEC”）存档，并可在SEC网站（。

www.SEC.gov

www.SEC.gov

). These forward-looking statements are made as of the date of this press release, and TriSalus assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

)。这些前瞻性声明是在本新闻稿发布之日做出的，TriSalus没有义务更新前瞻性声明，也没有义务更新实际结果可能与前瞻性声明中预测结果不同的原因，除非法律要求。